2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:45, 2 December 2023
, 2 December 2023→Bioavailability of NMN
| Line 103: | Line 103: | ||
While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | ||
* Taking 800 mg NMN | * Taking 800 mg NMN per day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | ||
* Taking 300 mg NMN per day increase serum NAD+ levels by ~38%.{{pmid|35821806}} | |||
== Controversy about NMN as Direct Precursor == | == Controversy about NMN as Direct Precursor == | ||